Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Eur J Immunol. 2015 Apr 24;45(6):1855–1867. doi: 10.1002/eji.201445245

Figure 6. AMD3100 treatment rapidly reduces both lymphoid and myeloid cells from bone marrow.

Figure 6

(A, B) WT mice (n=5/group) were injected with PBS or AMD3100, and sacrificed 2.5 h later. (A) Peripheral blood and bone marrow cells flushed from femurs were processed into single cell suspensions that were stained with fluorescently-labeled mAbs for flow cytometry. The femoral bone marrow content of the indicated cell types after PBS or AMD3100 treatment are shown. The percent values represent the reduction in each cell type in response to AMD3100. Results are from a single experiment representative of three independent experiments. Data are plotted for individual mice and summarized as the mean ± SEM. *p<0.05, **p<0.01, ****p<0.0001, two-tailed unpaired parametric t-test. (B) Bone marrow sections were stained with Ly6G-PE and B220-Alexa-Fluor 647 mAb. Images were collected by Leica SP5 confocal microscopy under 630X magnification. Data are from a single experiment with 2–5 mice tested in each group.